Recently, it was suggested that combining TIGIT blockade with PD-1/PD-L1 inhibitors could facilitate the differentiation of activated T cells into effector or memory T cells, thereby boosting anti-tumor immune responses [113]. The gene discussed is CD274; the disease is neoplasm.